A 62-year-old Indian woman undergoes total gastrectomy with D2 lymphadenectomy for T2 N1 gastric adenocarcinoma. Final histopathology shows 3 out of 18 regional lymph nodes involved. There is no peritoneal involvement, and margins are negative. What is the most appropriate next step in management?

Question

Accepted Answer

C. Adjuvant chemotherapy (ECF or FLOT regimen). ## Pathological Staging & Prognosis This patient has **T2 N1 M0 gastric cancer** (stage IIB by AJCC 8th edition). The presence of 1–2 positive regional lymph nodes (N1) indicates intermediate-risk disease requiring adjuvant therapy. ## Adjuvant Therapy Indications **Key Point:** Adjuvant chemotherapy is the standard of care for: - T2 with any N+ disease - T3/T4 regardless of N status - Patients who did not receive neoadjuvant chemotherapy **High-Yield:** The ACTS-GC trial (2018) demonstrated that adjuvant capecitabine + oxaliplatin (SOX) improves 5-year DFS from 53% to 65% in stage II–III gastric cancer. This is the most robust evidence for adjuvant chemotherapy in resected gastric cancer. ## Comparison of Adjuvant Strategies | Strategy | Indication | Evidence | Outcome | |----------|-----------|----------|----------| | Observation alone | T1 N0 only | — | Poor; 5-yr DFS ~60% for T2N1 | | Adjuvant chemotherapy | T2 N+, T3/T4 any N | ACTS-GC, GASTRIC meta-analysis | DFS improved 53% → 65%; OS improved | | Adjuvant radiotherapy alone | Rarely (R1 margin, diffuse type) | Weak evidence | Modest benefit; not standard | | Chemoradiotherapy | Locally advanced + R1 margin or high-risk features | INT-0116 (US data; less relevant in Asia) | Considered in selected cases, not routine | **Clinical Pearl:** The MAGIC trial used perioperative chemotherapy (neoadjuvant + adjuvant), but this patient did not receive neoadjuvant therapy. Adjuvant chemotherapy alone is therefore the appropriate next step to improve disease-free and overall survival. ## Decision Algorithm ```mermaid flowchart TD A[Resected gastric cancer
T2 N1 M0]:::outcome --> B{Neoadjuvant chemotherapy?}:::decision B -->|Yes| C[Adjuvant chemotherapy
x 3 cycles]:::action B -->|No| D[Adjuvant chemotherapy
x 6 cycles]:::action C --> E[Follow-up surveillance]:::outcome D --> E F[T1 N0] --> G[Observation]:::action H[R1 margin or
high-risk features] --> I[Consider chemoradiotherapy]:::action ``` **Mnemonic:** **ACTS** = **A**djuvant **C**apecitabine + oxaliplatin for **T**umors (stage II–III gastric cancer).

Answer

A. Adjuvant chemotherapy followed by chemoradiotherapy

Answer

B. Observation with regular follow-up endoscopy every 3 months

Answer

D. Adjuvant radiotherapy to the gastric bed

A 62-year-old Indian woman undergoes total gastrectomy with D2 lymphadenectomy for T2 N1 gastric adenocarcinoma. Final histopathology shows 3 out of 18 regional lymph nodes involved. There is no peritoneal involvement, and margins are negative. What is the most appropriate next step in management?

Explanation

Pathological Staging & Prognosis

Adjuvant Therapy Indications

Comparison of Adjuvant Strategies

Decision Algorithm

Practice similar questions

Join our NEET PG community

Strategy	Indication	Evidence	Outcome
Observation alone	T1 N0 only	—	Poor; 5-yr DFS ~60% for T2N1
Adjuvant chemotherapy	T2 N+, T3/T4 any N	ACTS-GC, GASTRIC meta-analysis	DFS improved 53% → 65%; OS improved
Adjuvant radiotherapy alone	Rarely (R1 margin, diffuse type)	Weak evidence	Modest benefit; not standard
Chemoradiotherapy	Locally advanced + R1 margin or high-risk features	INT-0116 (US data; less relevant in Asia)	Considered in selected cases, not routine